首页> 美国卫生研究院文献>Molecular Cellular Proteomics : MCP >Mining the Ovarian Cancer Ascites Proteome for Potential Ovarian Cancer Biomarkers
【2h】

Mining the Ovarian Cancer Ascites Proteome for Potential Ovarian Cancer Biomarkers

机译:挖掘卵巢癌腹水蛋白质组作为潜在的卵巢癌生物标志物

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Current ovarian cancer biomarkers are inadequate because of their relatively low diagnostic sensitivity and specificity. There is a need to discover and validate novel ovarian cancer biomarkers that are suitable for early diagnosis, monitoring, and prediction of therapeutic response. We performed an in-depth proteomics analysis of ovarian cancer ascites fluid. Size exclusion chromatography and ultrafiltration were used to remove high abundance proteins with molecular mass ≥30 kDa. After trypsin digestion, the subproteome (≤30 kDa) of ascites fluid was determined by two-dimensional liquid chromatography-tandem mass spectrometry. Filtering criteria were used to select potential ovarian cancer biomarker candidates. By combining data from different size exclusion and ultrafiltration fractionation protocols, we identified 445 proteins from the soluble ascites fraction using a two-dimensional linear ion trap mass spectrometer. Among these were 25 proteins previously identified as ovarian cancer biomarkers. After applying a set of filtering criteria to reduce the number of potential biomarker candidates, we identified 52 proteins for which further clinical validation is warranted. Our proteomics approach for discovering novel ovarian cancer biomarkers appears to be highly efficient because it was able to identify 25 known biomarkers and 52 new candidate biomarkers that warrant further validation.
机译:由于其相对较低的诊断敏感性和特异性,当前的卵巢癌生物标志物不足。有必要发现和验证适用于早期诊断,监测和预测治疗反应的新型卵巢癌生物标志物。我们对卵巢癌腹水进行了深入的蛋白质组学分析。使用尺寸排阻色谱法和超滤法去除分子量≥30 kDa的高丰度蛋白质。胰蛋白酶消化后,通过二维液相色谱-串联质谱法测定腹水液的亚蛋白质组(≤30kDa)。筛选标准用于选择潜在的卵巢癌生物标志物候选物。通过组合来自不同尺寸排阻和超滤分离方案的数据,我们使用二维线性离子阱质谱仪从可溶性腹水组分中鉴定出445种蛋白质。在这些蛋白质中,有25种先前被鉴定为卵巢癌生物标志物的蛋白质。在应用一套过滤标准以减少潜在的生物标志物候选物的数量后,我们鉴定了52种需要进一步临床验证的蛋白质。我们的蛋白质组学方法用于发现新型卵巢癌生物标记物似乎是高效的,因为它能够鉴定出25种已知生物标记物和52种新候选生物标记物,需要进一步验证。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号